Regardless, the absence of STAT6 immunostaining in a tumor with morphologic features consistent with SFT/HPC should lead to the consideration of molecular testing to assess for the presence of NAB2–STAT6 fusion. The gene discussed is NAB2; the disease is neoplasm.